We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.015 | 0.72% | 2.09 | 2.01 | 2.09 | 2.09 | 2.05 | 2.05 | 640,574 | 10:01:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.80 | 6.83M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/12/2017 15:44 | The volume is quite good today and the price has held, which is a good sign. | ashehzi | |
20/12/2017 15:06 | Therapy Focus - Lupus Hopes Build But Data Remain On The Distant Horizon hxxps://seekingalpha | jpleight | |
20/12/2017 13:50 | No ...gave that up when I sold out at 50.375pps in Dec 2013.... | badger60 | |
20/12/2017 13:46 | Badger your wanted on the QFI threadThe resident pessimists are back | kop202 | |
20/12/2017 13:01 | Added 10k under 150p that I had previously sold above 170p. Can't resist a bargain. | divmad | |
20/12/2017 12:54 | Badger and ALL the depampers only appear when there is fear! He wants to buy cheaper...and he wants YOUR shares Cheaper!!!! | flavio_monteiro | |
20/12/2017 12:46 | Badger is just a wind up merchant don't take the bate | best1467 | |
20/12/2017 12:44 | Been advised today by IMM they will definately issue another Update when the last patient has received their last dose in the current Phase 3 Lupuzor trial, but they cannot privately disclose the day in advance on an individual shareholder basis. Also confirmed that once the last patient commenced dosing earlier this year (Update, 25/1/2017) the timetable for their dosings and evaluations was fixed (in accordance with the trial design) and will not alter; so it becomes quite straightforward to predict the last patient evaluation is in January, with the last dose 28 days beforehand. | hottingup | |
20/12/2017 12:41 | Ignore badger, hasn’t a clue, a bit like arab Hope you guys got into (VELA) when I mentioned them here months ago, along with (BLU), fortune being made, Blockchain is going to be huge in ‘18 | ny boy | |
20/12/2017 12:38 | Badger, IMM staged a fundraising in early 2017 to provide cash through 2018. With the Phase 3 Lupuzor ending in January 2018 cash burn drops dramatically. Good Lupuzor results in January will mean the company is flooded with deal and takeover offers. | englishlongbow | |
20/12/2017 12:37 | badger, raise 6 mil? 1-2 mil shares come the end of Jan? deary me? | wossupsa | |
20/12/2017 12:30 | raise money ? I will worry when the company buys a big new office with private jet brochures in reception.So not now. | bolador | |
20/12/2017 12:29 | Thanks Santa 🎅 Some more sobbing after being right royally mugged! | ny boy | |
20/12/2017 12:27 | Black in the blue now, glad I topped up at £1.41. Always best to top up on any pull backs with this share | spmc | |
20/12/2017 12:23 | I am now starting to see the rationale for enforced culling of badgers - isn't it because they spread disease and disrupt natural harmony? OD | obiterdicta | |
20/12/2017 12:22 | aussieb3 - is she a blond by any chance? | lord gnome | |
20/12/2017 12:19 | looks like badger has gone to ground. Hopefully to hibernate for the rest of the winter | spawny100 | |
20/12/2017 12:16 | Back at £1.50 now, we should get a £1.60 close and then £1.70 tommorrow | spmc | |
20/12/2017 12:16 | Back at £1.50 now, we should get a £1.60 close and then £1.70 tommorrow | spmc | |
20/12/2017 12:11 | I said to girlfriend immupharma dropped today , lol she said people want money out for x mas presents . This is her who say the Euro has gone up in June because people are going on holiday. The joys | aussieb3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions